Biodexa US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

 Underscores unmet need for a therapeutic alternative with the potential to delay or prevent surgical removal of the colon and/or rectum

Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announced today that the US Food and Drug Administration (“FDA”) has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the treatment of familial adenomatous polyposis (FAP). Fast track designation is intended to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need.

https://www.globenewswire.com/news-release/2025/02/10/3023436/0/en/Biodexa-Receives-US-FDA-Fast-Track-Designation-for-eRapa-in-Familial-Adenomatous-Polyposis.html